- Emerging prenatal screening technologies perform in real clinical scenarios
- The RiskScore assessment more accurately identifies breast cancer risk to enable more precise, personalized risk stratification and management across diverse patient populations.
Innovations at Myriad Genetics: FirstGene Multiple Prenatal Screen and MyRisk with RiskScore Breast Cancer Risk Assessment
2026 NSGC ANNUAL CONFERENCE LUNCH SYMPOSIUM*
Genetic testing continues to evolve, creating opportunities to personalize patient care across specialties. This session will provide an overview of the recent innovation from Myriad Genetics, including the new FirstGene® Multiple Prenatal Screen and enhancements to the MyRisk® with RiskScore® Breast Cancer Risk Assessment test.
Participants will learn how:
Lunch and beverages will be provided. This event is exclusively for registered 2026 NSGC Annual Conference attendees.
*This symposium is supported by Myriad Genetics through a marketing grant. Not CME-accredited.
LIMITED SEATING. RSVP NOW.
SPEAKERS
Sabrina Williams, MS, CGC
Myriad Genetics
Sabrina Williams is a licensed, certified genetic counselor with Myriad Genetics - Family Health. She has expertise reproductive, pediatric, and hereditary cancer genetics and has spent more than a decade directly involved in patient care serving patients in the southeast. She is passionate about the role of genetics and genetic testing in personalized medicine and its ability to profoundly impact outcomes for not just the individual patient, but the families in our communities. Her role at Myriad has afforded her the opportunity to help educate and empower clinicians to ensure the families they see every day receive the quality genetic services they deserve.
Dale Muzzey, Ph.D.
Myriad Genetics
Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.
Natalie Jones, MS, CGC
Myriad Genetics
Natalie Jones is a licensed, certified genetic counselor with Myriad Genetics - Oncology, where she collaborates with healthcare professionals to advance the integration of genetic and genomic information into oncology care. Prior to joining Myriad Genetics, she practiced clinically at UMass Memorial Medical Center where she provided genetic counseling services to both pediatric and adult oncology patients. In addition to her clinical experience, Natalie has contributed to research involving polygenic risk scores and is passionate about advancing health equity and expanding access to genetic and genomic services. Her professional interests include improving the delivery of precision medicine, increasing access to genetic counseling, and supporting the responsible implementation of emerging genomic technologies in clinical practice.
About Myriad Genetics®
Myriad Genetics is a leader in molecular diagnostic testing and precision medicine with offerings in oncology, women’s health and pharmacogenomics. Myriad tests and screenings provide personalized insights that help healthcare providers better prevent disease, assess disease risks, and guide treatment decisions. For more than 30 years, Myriad’s scientific expertise and innovation have brought actionable genetic insights to millions of patients. For more information, visit https://myriad.com/.
We Are Live In
Myriad Genetics, Inc. / 322 North 2200 West, Salt Lake City, UT 84116 ©2026 Myriad Genetics, Inc. Myriad Genetics, FirstGene, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.